International Journal of Basic Science in Medicine. Volume 3, Issue 3, 2018 134 brain including cortex, hippocampus, and substantial nigra. 3 It has been proven that subcutaneous and intraperitoneal injection of G-CSF results in neural protection in substantial nigra via increasing B-cell lymphoma 2 (Bcl-2) and decreasing Bcl-2-associated X protein (Bax) leading to the reduction of neural apoptosis. 4, 5 In addition, expression of G-CSF and its receptor are increased shortly after ischemia induction suggesting a role for G-CSF in endogenous response to ischemic conditions. 6 The VEGF is another factor which is secreted by 4T1 cells. Many studies have indicated that administration of VEGF decreased infarct volume, increased neural survival, and finally enhanced neurogenesis in the subventricular zone (SVZ) and hippocampus. It has also increased angiogenesis in brain ischemia ameliorating behavioral deficit. 7 Transplantation of VEGF overexpressing transgenic cells showed neuroprotective effects in brain ischemia. 8 Moreover, pathologic effects of 4T1 cells are limited to BALB/c mice therefore their transplantation in rats' brain are safe.
The Sertoli cells (SCs) support the cells in the testis and are known as the 'nurse cells' because of their ability to protect and increase the survival of germ cells. Their tightjunctions make a physical barrier that is important in protecting germs cells from unwanted immune reactions. These cells also suppress immune system by secreting interleukin 2 (IL-2) inhibitor factor. 9 Transforming alpha and beta (TGF-α & TGF-β) growth factors, insulin-like growth factor (IGF-I), fibroblast growth factor (FGF-2), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3), basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) are among other secretions which present neuroprotective effects by the SCs. 10, 11 The injection of SCs into the spinal cord improved motor neuron survival in animal models of amyotrophic lateral sclerosis via their trophic factors. 12 It has been demonstrated that injection of SCs derived growth factors exerted neuroprotective effects. For example, TGF-β1, one of the SCs secreted factors, protected the structure of blood-brain barrier (BBB) via reduction of matrix metallopeptidase (MMP-2/9) expression. 13 Besides, GDNF administration reduced neural apoptosis and improved neural disorders in ischemia and Parkinson disease. 14 Previous studies have indicated that co-transplantation of SCs and islet xenografts increased the survival of transplanted cells by suppressing the immune system. 15 Co-culture of SCs with endothelial and neural stem cells can also enhance their proliferation and survival. 16 Another study has revealed that co-culture of SCs and bone marrow mesenchymal stem cells provide an environment that enhances stem cells proliferation via epidermal growth factor (EGF) signaling pathway. 17 It has been revealed that allograft of dopaminergic neurons with SCs improved the survival of grafted neurons through modulating the immune responses. 18 Regarding beneficial effects of 4T1 and SCs cells toward cellular protection in allografts, the researchers of the present study evaluated the possible neuroprotective effect of 4T1 and SCs on infarct volume of brain damage, brain edema, and damages of BBB in mouse models of brain ischemia.
Materials and Methods

Animals
Sixty male Wistar rats (230 to 290 g) were purchased from Pasteur Institute (Karaj, Iran). Rats were randomly divided into 5 groups and during all the experiments, they had free access to water and standard food. All the rats were kept at the same animal facility with a 12:12 hours of a dark-light cycle at 25°C.
Experimental Protocol
The experimental groups consisted of control, sham, and 3 treatment groups receiving either 4T1, SCs, or 4T1+SCs cells by the stereotaxic method. In the control group, middle cerebral artery occlusion (MCAO) surgery was performed on the rats. A surgery without the entrance of coated nylon suture was performed in sham group to mimic the stress of surgery. In the treatment groups, 4T1, SCs, and 4T1+SCs cells were injected into the right striatum three days prior to the MCAO surgery.
Focal Cerebral Ischemia
The animals were anesthetized with intraperitoneally injected chloral hydrate (400 mg/kg). The MCAO surgery was done according to the previously described method by Longa et al. 19 Briefly, 20-22 mm of 3-0 silicone coated nylon suture was guided to reach bifurcation of the carotid throughout the internal carotid artery (ICA) until a mild resistance was recognized which meant the tip was stuck to the anterior cerebral artery and blocked the middle cerebral artery.
Sertoli Cells Extraction
Testes were removed from adult rats, cut into small pieces, and moved into the tubes containing media and antibiotics. Tissues were incubated at 37°C with trypsin (0.25%) for 15 minutes. After aspiration of the trypsin, 1% collagenase solution was added and incubated for 15 minutes at 37°C. Fetal bovine serum (FBS) was added and the samples were centrifuged. Cells were moved to the culture flasks with DMEM/F12 with 10% FBS and vancomycin (25 mg/1 L DMEM). The SCs were incubated with Hoechst prior to the injection. The cells were then centrifuged and were counted with trypan blue. For SCs and 4T1+SCs receiving groups, 5x10 5 and 2.5x10 5 (total of 5x10 5 ) cells were prepared for injection, respectively.
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4T1 Cells Culture The 4T1 cell line was obtained from Pasteur Institute (Tehran, Iran). Cells were cultured in DMEM/F12 with 10% FBS and vancomycin (25 mg/1 L DMEM). They were also counted before the injection as described before. The number of 5x10 5 and 2.5x10 5 cells were prepared for 4T1 and 4T1+SCs (total of 5x10 5 ) receiving group, respectively.
Cell Injection
The animals were anesthetized and fixed in stereotaxic apparatus. According to the Paxinos atlas, cells were transplanted into the right striatum and the coordinates were as follows: Bregma = 0.96, Lateral = 3 mm, and DV = 5 mm.
Neurobehavioral Evaluation Twenty-four hours after reperfusion, NSS was measured according to the previously described method, 21 which contained 5 parts (i.e., raise tail, sensory function, motor function, beam, and reflex tests) and the maximum score of 18.
Assessment of Infarct Volume
The assessment was conducted by previously described method. 22 Briefly, the rats were sacrificed 24 hours after reperfusion and their brains were kept in saline at 4°C for 10 minutes. The brains were then cut, with a thickness of 2 mm, followed by incubation for 15 minutes with 2,3,5-Triphenyltetrazolium chloride 2% (TTC) at 37°C. The following formula was used in this regard: Corrected infarct volume = Left hemisphere volume -(Right hemisphere volume -Infarct volume) Analysis of Brain Water Content Wet weight (WW) and dry weight (DW) of different parts of the brain including cortex, striatum, and Pir-Amy were measured after 24 hours of incubation at 120°C. At the end, brain water content was assessed by previously explained formula 23 as follows:
Assessment of BBB Permeability The BBB permeability was checked using Evans blue (Eb). In summary, 30 minutes after MCAO surgery, 2% EB 4 mL/kg was injected into the tail vein. Perfusion with saline was performed and different parts of the brain were weighted 24 hours after the surgery (FEW,FH-300H, Japan). Brains were homogenized (Sonoplus Ultrasonic, HD2070-HD22500) in phosphate-buffered saline and were later mixed with trichloroacetic acid (60%) and kept at 4°C for 30 minutes. Samples were centrifuged and the absorbance of supernatants were read at 610 nm by spectrophotometer (Analytikjena, Spercord, 210).The level of EB was stated as μg/g of the brain tissue. 23 
Statistical Analysis
One-way analysis of variance (ANOVA) test was used to compare different parameters among the groups. As post hoc Tukey HSD test, LSD (the least significant difference) was employed and the statistical significance was represented as P<0.05. In addition, nonparametric Kruskal-Wallis test was applied for analyzing neurological severity scores (NSSs).
Results
Effect of 4T1 and SCs Allograft Transplantation and Cotransplantation on Neurologic Deficit Scores All treatments including SCs, 4T1, and 4T1+SCs cotransplantation reduced total neurological NSS. The scores were 11 (range: 8-12), 9 (range: 5-11), and 9 (range: 5-13), respectively as compared to 14 (range: 13-15) in the control group (Table 1) . The results revealed that sensory function and beam test were also improved significantly in all the treatment groups compared to the control group. Moreover, an improvement was noted in raise tail test in SCs and 4T1+SCs receiving groups compared to the control group. The distribution of NSS in different groups under investigation is provided in Table 1 .
Effect of 4T1 and SCs Allograft Transplantation and Cotransplantation on Infarct Volume Allograft transplantation of SCs, 4T1, and 4T1+SCs co-transplantation three days before MCAO surgery decreased the total infarct volume respective to the control group.
The obtained results indicated a significant reduction (Figure 2 ).
Effect of 4T1 and SCs Allograft Transplantation and Cotransplantation on BBB Permeability As compared with the control group, BBB permeability was reduced in the right cortex as well as striatum of SCs and 4T1+SCs treated groups and also right Pir-Amy of SCs treated group while no significant reduction was found in other experimental groups (Figure 3 ).
Discussion
According to the results, it was noted that transplantation and co-transplantation of SCs and 4T1 cells resulted in improvement of neurological deficits after brain ischemia. The cell treatment also ameliorated the infarct volume in majority of the brain areas including cortex, Pir-Amy, and striatum. Moreover, BBB permeability and brain edema were improved in groups treated with SCs, but not in 4T1 receiving group probably because of the VEGF secretion It has been revealed that intravenous injection of VEGF one hour after the ischemia increased BBB leakage and edema due to an elevation in brain microvascular permeability to blood plasma proteins. 24 Studies have illustrated that VEGF had different effects on brain ischemia depending on the time of administration. 25 In another study, it was also found that intravenous injection of VEGF one hour after ischemia failed to protect damages while its administration four hours after ischemia improved the neurological disorders. 25 As it has been reported in another study, hypoxic preconditioning increased VEGF levels in an early stage of brain ischemia which resulted in dysregulation of BBB. 26 Although it seems that the administration of VEGF in early stage of brain ischemia may induce brain edema and BB disruption, many studies have revealed its neuroprotective roles in brain ischemia. It has been reported that VEGF reduced the infarct volume, 27 improved neurological disorders, and increased the mesencephalic neurons survival. 28 Studies have also indicated that VEGF had a direct mitogenic effect on neurons. 29 The injection of VEGF 1 to 48 hours after the ischemia improved behavioral dysfunctions in rotarod and adhesion removal test. 24 The VEGF enhanced neural survival and decreased toxicity in in vitro models of the brain ischemia. Researches have shown that transplantation of VEGF and BDNF secreting cells improved neural disorders. 8 Transplantation of VEGFoverexpressed transgenic neural stem cells ameliorated behavioral dysfunction following the brain ischemia. 30 Another main characteristic of 4T1 cell was their ability to produce G-CSF. 1 Studies have shown that G-CSF reduced neural apoptosis in brain ischemia by reduction of caspase 3 through phosphoinositide 3-kinase/protein kinase (PI3/Akt) signaling pathway. 3 They have also illustrated that injection of G-CSF decreased infarct volume, inflammation, and brain edema following brain ischemia via STAT (signal transducer and activator of transcription protein) signaling pathway. 31 Similarly, it has been reported that the administration of human recombinant G-CSF ameliorated neurological disorders and decreased infarct volume by increasing Bcl-2 expression. 5 Besides, it has been indicated that G-CSF maintained BBB structure and permeability in ischemic conditions by increasing claudin-5 and decreasing intercellular adhesion molecule 1 (ICAM-I) and vascular cell adhesion protein (VCAM-I) in endothelial cells via PI3/Akt signaling pathway. 32 In addition, it was found that G-CSF decreased hemisphere atrophy and infarct volume by increasing the vessel density and angiogenesis. 33 According to the results obtained by another study, subcutaneous injection of G-CSF also reduced infarct volume and permeability of BBB following the ischemia. 34 Moreover, transplantation of SCs in the striatum of Huntington animal models ameliorated locomotor abnormalities. 12 Injection of microencapsulated SCs in the striatum, improved the neural deficits in the rat models of Huntington via producing growth factors. 35 According to previous studies, cells with the ability of GDNF secretion can be valuable targets in cell therapy. The GDNF was found to decrease the neural apoptosis through increasing Bcl-2 expression in Parkinson disease.
14 Immunocytochemistry test results confirmed the identity of SCs and the researchers of the current study have revealed that these cells were able to secrete VEGF and GDNF (data is not represented). The GDNF decreased apoptosis and helped endothelial cells to keep their structure in BBB. It has also been demonstrated that GDNF reduced infarct volume and brain edema. 36 Although SCs transplantation resulted in neural survival, SCs co-transplantation with other cells like 4T1 cells prolonged the survival of grafted cells. Infusion of SCs with grafted islet cells has been found to reduce peripheral lymphocyte activation and inflammatory cytokine levels. 37 Moreover, ventral mesencephalon neutrons and SCs co-transplantation in striatum increased survival of grafted cells.
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Conclusion
Generally speaking, transplantation of 4T1 cells resulted in neuroprotection probably through production of high level growth factors such as VEGF and G-CSF. The SCs co-transplantation with 4T1 cells not only protected grafted cells system, but also enhanced neural survival.
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